The enteral feeding devices market was valued at USD 3,735.79 million in 2021 and is expected to reach USD 5,451.06 million by 2027, registering a CAGR of 6.50% over the forecast period.
The COVID-19 pandemic is expected to significantly impact the enteral feeding devices market globally. According to a research article published in Critical Care, 2020, the SARS-CoV2 virus infects the respiratory tract and is also predicted to invade the gastrointestinal tract, neurological systems, and kidneys, which may affect the nutrition delivery among COVID-19 patients. According to guidelines by the European Society for Clinical Nutrition and Metabolism (ESPEN) on nutrition in the ICU, gastric enteral nutrition is advised for severe COVID-19 patients and should be preferably performed using a pump with a flow regulator within 48 hours of admission to the ICU. Hence, the COVID-19 pandemic increased the need for enteral feeding devices, especially for those in intensive care units, and has been driving the market studied.
The factors responsible for the market’s growth include the rising burden of chronic diseases, the increasing number of premature deaths, and the growing demand for enteral feeding in-home care settings.
The rising burden of chronic diseases is a major factor driving the market’s growth. For instance, as per the GLOBOCAN 2020, an estimated number of 1.09 million new stomach cancer cases were identified in 2020 globally, and the number is estimated to reach 1.77 million by 2040. As patients suffering from stomach cancer require the support of enteral nutrition, the statistics indicate that the demand for enteral feeding devices is anticipated to increase over the coming period. As per a 2022 update by the International Foundation for Gastrointestinal Disorders (IFFGD), 10 to 15% of the population is affected by irritable bowel syndrome worldwide. Thus, the high burden of chronic diseases is leading to an increased demand for enteral feeding devices, thereby contributing to market growth.
However, complications associated with enteral feeding tubes and healthcare reimbursement issues are the major factors restraining the market’s growth.
By application, the diabetes segment is expected to witness significant growth during the forecast period. The major factors fueling the growth of the segment are the increasing burden of diabetes, the growing geriatric population, and the increasing implementation of strategic initiatives by market players.
For instance, incidences of diabetes have increased over the years globally and are expected to increase further. As per a 2021 update by the International Diabetes Federation (IDF), approximately 537 million adults (20-79 years) are living with diabetes. As per the same source, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. The source also reports that 1 in 4 adults with diabetes live in low- and middle-income countries, and almost 1 in 2 (240 million) adults living with diabetes are undiagnosed.
Several market players are also engaged in implementing strategic initiatives, which is contributing to market growth. For instance, in July 2021, Medtronic Diabetes received approval from the US Food and Drug Administration (FDA) for its extended-wear infusion set, designed to last more than twice as long as existing infusion sets that connect traditional tubed pumps to the body for insulin delivery.
Thus, these factors play a major role in increasing the demand for enteral feeding devices, which is expected to boost the market’s growth.
The North American region, particularly the United States, has a developed and well-structured health care system. The region is a hub for research and development activities and encourages key players to establish their headquarters in the region through its policies and investment support. As a result, these countries enjoy the presence of many global market players.
Increases in the burden of chronic diseases, geriatric population, and surgical procedures in the region are expected to drive the demand for enteral feeding devices to support the nutritional requirements of individuals who cannot ingest and digest food. For instance, as per the 2020 statistics by the US Department of Health and Human Services, approximately 39,034 liver transplants were performed in the United States in 2020. As enteral nutrition support is required in patients undergoing liver transplantation, the statistics indicate significant demand for enteral feeding devices in the country.
Additionally, as per statistics by the IDF Diabetes Atlas, 10th Edition, in 2021, the number of people identified with diabetes in thousands was 32,215.3 in the United States, and the number is estimated to reach 36,289.9 by 2045. Diabetes patients are likely to have a threefold higher risk of being hospitalized. Many of the consequences of improperly managed diabetes, such as strokes, can necessitate enteral feeding. Thus, the statistics indicate the increasing demand for enteral feeding devices in the country.
Moreover, market players are engaged in various strategies that are contributing to market growth. For instance, in May 2021, QMD reported the addition of Nasogastric Tubes to its Degania Enteral Feeding Product Portfolio. Nasogastric Tubes are manufactured from premium materials and designed to comply with ENFit connection standards for improved patient safety.
Thus, due to the abovementioned developments, the market is expected to witness significant growth over the forecast period.
The enteral feeding devices market is highly competitive. In terms of market share, several companies, such as B. Braun Melsungen AG, Boston Scientific Corporation, Conmed Corporation, Cardinal Health, and Becton Dickinson and Company, among others, hold the highest market shares. The key players are evolving through various strategic alliances, such as acquisitions, collaborations, and new product launches, to expand the global product portfolio and secure their positions in the global market.
This product will be delivered within 2 business days.
The COVID-19 pandemic is expected to significantly impact the enteral feeding devices market globally. According to a research article published in Critical Care, 2020, the SARS-CoV2 virus infects the respiratory tract and is also predicted to invade the gastrointestinal tract, neurological systems, and kidneys, which may affect the nutrition delivery among COVID-19 patients. According to guidelines by the European Society for Clinical Nutrition and Metabolism (ESPEN) on nutrition in the ICU, gastric enteral nutrition is advised for severe COVID-19 patients and should be preferably performed using a pump with a flow regulator within 48 hours of admission to the ICU. Hence, the COVID-19 pandemic increased the need for enteral feeding devices, especially for those in intensive care units, and has been driving the market studied.
The factors responsible for the market’s growth include the rising burden of chronic diseases, the increasing number of premature deaths, and the growing demand for enteral feeding in-home care settings.
The rising burden of chronic diseases is a major factor driving the market’s growth. For instance, as per the GLOBOCAN 2020, an estimated number of 1.09 million new stomach cancer cases were identified in 2020 globally, and the number is estimated to reach 1.77 million by 2040. As patients suffering from stomach cancer require the support of enteral nutrition, the statistics indicate that the demand for enteral feeding devices is anticipated to increase over the coming period. As per a 2022 update by the International Foundation for Gastrointestinal Disorders (IFFGD), 10 to 15% of the population is affected by irritable bowel syndrome worldwide. Thus, the high burden of chronic diseases is leading to an increased demand for enteral feeding devices, thereby contributing to market growth.
However, complications associated with enteral feeding tubes and healthcare reimbursement issues are the major factors restraining the market’s growth.
Key Market Trends
Diabetes Segment Expected to Witness Significant Growth During the Forecast Period
By application, the diabetes segment is expected to witness significant growth during the forecast period. The major factors fueling the growth of the segment are the increasing burden of diabetes, the growing geriatric population, and the increasing implementation of strategic initiatives by market players.
For instance, incidences of diabetes have increased over the years globally and are expected to increase further. As per a 2021 update by the International Diabetes Federation (IDF), approximately 537 million adults (20-79 years) are living with diabetes. As per the same source, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. The source also reports that 1 in 4 adults with diabetes live in low- and middle-income countries, and almost 1 in 2 (240 million) adults living with diabetes are undiagnosed.
Several market players are also engaged in implementing strategic initiatives, which is contributing to market growth. For instance, in July 2021, Medtronic Diabetes received approval from the US Food and Drug Administration (FDA) for its extended-wear infusion set, designed to last more than twice as long as existing infusion sets that connect traditional tubed pumps to the body for insulin delivery.
Thus, these factors play a major role in increasing the demand for enteral feeding devices, which is expected to boost the market’s growth.
North America Expected to Dominate the Enteral Feeding Devices Market over the Forecast Period
The North American region, particularly the United States, has a developed and well-structured health care system. The region is a hub for research and development activities and encourages key players to establish their headquarters in the region through its policies and investment support. As a result, these countries enjoy the presence of many global market players.
Increases in the burden of chronic diseases, geriatric population, and surgical procedures in the region are expected to drive the demand for enteral feeding devices to support the nutritional requirements of individuals who cannot ingest and digest food. For instance, as per the 2020 statistics by the US Department of Health and Human Services, approximately 39,034 liver transplants were performed in the United States in 2020. As enteral nutrition support is required in patients undergoing liver transplantation, the statistics indicate significant demand for enteral feeding devices in the country.
Additionally, as per statistics by the IDF Diabetes Atlas, 10th Edition, in 2021, the number of people identified with diabetes in thousands was 32,215.3 in the United States, and the number is estimated to reach 36,289.9 by 2045. Diabetes patients are likely to have a threefold higher risk of being hospitalized. Many of the consequences of improperly managed diabetes, such as strokes, can necessitate enteral feeding. Thus, the statistics indicate the increasing demand for enteral feeding devices in the country.
Moreover, market players are engaged in various strategies that are contributing to market growth. For instance, in May 2021, QMD reported the addition of Nasogastric Tubes to its Degania Enteral Feeding Product Portfolio. Nasogastric Tubes are manufactured from premium materials and designed to comply with ENFit connection standards for improved patient safety.
Thus, due to the abovementioned developments, the market is expected to witness significant growth over the forecast period.
Competitive Landscape
The enteral feeding devices market is highly competitive. In terms of market share, several companies, such as B. Braun Melsungen AG, Boston Scientific Corporation, Conmed Corporation, Cardinal Health, and Becton Dickinson and Company, among others, hold the highest market shares. The key players are evolving through various strategic alliances, such as acquisitions, collaborations, and new product launches, to expand the global product portfolio and secure their positions in the global market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value- USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- B. Braun Melsungen AG
- Boston Scientific Corporation
- Conmed Corporation
- Cook Medical Inc.
- Fresenius SE & Co. KGaA
- Halyard Health Inc.
- Nestle SA
- Avanos Medical Inc.
- Cardinal Health Inc.
- Becton Dickinson and Company
- Vygon SA
- Applied Medical Technology Inc.
- Amsino International Inc.
- Fidmi Medical
- ALCOR Scientific Inc.
Methodology
LOADING...
